Table 4.
MICs of AFN-1252 and comparators for panels of diverse staphylococci
| Panel, isolate group (no. of isolates), and agent | MIC (μg/ml) |
||
|---|---|---|---|
| 50%d | 90%e | Range | |
| 1, genotyped U.S. S. aureus isolatesa | |||
| USA300 (26) | |||
| AFN-1252 | 0.015 | 0.015 | 0.008–0.06 |
| Vancomycin | 0.5 | 0.5 | 0.5–0.5 |
| Daptomycin | 0.25 | 0.25 | 0.12–0.25 |
| Linezolid | 2 | 2 | 1–2 |
| Other CA-MRSAa isolates (36) | |||
| AFN-1252 | 0.008 | 0.03 | 0.004–0.06 |
| Vancomycin | 0.5 | 1 | 0.5–1 |
| Daptomycin | 0.25 | 0.25 | 0.12–0.25 |
| Linezolid | 1 | 2 | 1–2 |
| HA-MRSA isolates (17) | |||
| AFN-1252 | 0.008 | 0.015 | 0.008–0.125 |
| Vancomycin | 1 | 1 | 0.5–1 |
| Daptomycin | 0.12 | 0.25 | 0.12–0.5 |
| Linezolid | 2 | 2 | 1–2 |
| MSSAb isolates (21) | |||
| AFN-1252 | 0.008 | 0.015 | 0.004–0.015 |
| Vancomycin | 0.5 | 1 | 0.5–1 |
| Daptomycin | 0.12 | 0.25 | 0.06–0.5 |
| Linezolid | 1 | 2 | 0.5–2 |
| 2, Canadian S. aureus isolatesb | |||
| MSSA (104) | |||
| AFN-1252 | 0.008 | 0.008 | 0.004–0.06 |
| Vancomycin | — | — | ≤2 |
| Daptomycin | 0.25 | 0.5 | ≤0.06–0.5 |
| Linezolid | 2 | 2 | ≤1–4 |
| MRSA isolates (86) | |||
| AFN-1252 | 0.008 | 0.016 | 0.004–0.12 |
| Vancomycin | — | — | ≤2 |
| Daptomycin | 0.25 | 0.5 | 0.25–0.5 |
| Linezolid | 2 | 2 | ≤1–4 |
| 3, 100 Canadian coagulase-negative Staphylococcus isolatesc | |||
| S. lugdunensis (52) | |||
| AFN-1252 | 0.008 | 0.016 | 0.002–>0.25 |
| Vancomycin | ≤2 | ≤2 | ≤2 |
| Daptomycin | 0.25 | 0.25 | ≤0.06–1 |
| Linezolid | ≤1 | ≤1 | ≤1 |
| S. epidermidis isolates (27) | |||
| AFN-1252 | 0.016 | 0.12 | ≤0.001–>0.25 |
| Vancomycin | ≤2 | ≤2 | ≤2 |
| Daptomycin | 0.5 | 1.0 | 0.25–1 |
| Linezolid | ≤1 | ≤1 | ≤1–2 |
| Other coagulase-negative Staphylococcus isolates (21) | |||
| AFN-1252 | 0.016 | 0.25 | 0.002–>0.25 |
| Vancomycin | ≤2 | ≤2 | ≤2 |
| Daptomycin | 0.12 | 1.0 | 0.12–1 |
| Linezolid | ≤1 | ≤1 | ≤1–2 |